Insight Innovation: Die riskante Wette auf den ersten Impfstoff gegen Krebs
Hautkrebs könnte bald mit demselben Prinzip bekämpft werden, mit dem schon das Coronavirus gebändigt wurde. Moderna und Merck melden Erfolge mit einem mRNA-Impfstoff. Doch es gibt Hürden.
Munich witnessed Moderna's first major breakthrough in 2021, amid the rampant Covid-19 pandemic. Under the leadership of Stéphane Bancel, Moderna announced robust test data for a Covid-19 vaccine. Five years later, the biotech giant is aiming for another medical milestone, this time battling cancer. It's the most risky and costly bet of the US biotech company.
Before the end of last week, the pharmaceutical world looked skeptically on the project. Then, Moderna surprisingly announced positive test results for an innovative skin cancer vaccine. Developed jointly with US pharmaceutical giant Merck & Co, it's the first messenger RNA (mRNA) drug to excel in a large, licensable clinical trial.
The drug could hit the market by 2027. Researchers and analysts are hailing it as a scientific breakthrough. Wall Street analysts anticipate billion-dollar revenues, and even tech investors are impressed. Could the same principle used to curb coronavirus soon help in combating skin cancer?
Written by urgent.news from Handelsblatt's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
